Zasocitinib for hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests a new daily pill called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. It aims to reduce painful lumps and abscesses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had HS symptoms for at least 6 months and a doctor confirmed your diagnosis.
- You have HS lesions in at least 2 body areas, and at least one area is stage II or III (moderate to severe).
- You have at least 5 painful bumps or abscesses at both the screening and first visit.
- You have tried an oral antibiotic for HS that didn't work well enough, or you couldn't take it.
- You are 18 or older and agree to use effective birth control if needed.
- You do not have active infections, certain other skin conditions, or serious health problems (like heart or liver issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This study tests an oral medicine called ritlecitinib for moderate to severe hidradenitis suppurativa (HS) in adults who haven't responded well to antibiotics. The goal is to see if it can reduce painful red lumps and improve quality of life.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests an injected drug called siplizumab for people with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with other treatments. The goal is to see if it safely reduces painful bumps and improves your skin condition.
This study tests a new medicine called LAD191 for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. Researchers want to see if LAD191 safely reduces painful bumps and tunnels.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.